(rel)-Oxaliplatin NEW
| Price | $1520 | $1980 | $2500 |
| Package | 25mg | 50mg | 100mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-04-29 |
Product Details
| Product Name: (rel)-Oxaliplatin | CAS No.: 63121-00-6 |
| Supply Ability: 10g | Release date: 2025/04/29 |
Product Introduction
Bioactivity
| Name | (rel)-Oxaliplatin |
| Description | (rel)-Oxaliplatin, a DNA synthesis inhibitor, induces DNA crosslinking damage, inhibits DNA replication and transcription, and stimulates apoptosis. This compound has applications in cancer research [1] [2] [3]. |
| In vitro | (rel)-Oxaliplatin demonstrates potent anticancer activity through various mechanisms across multiple cell lines. When applied to HCC, HCCLM3, and Hep3B cells for 24-72 hours at concentrations of 2-128 μM, it inhibits cell proliferation and triggers apoptosis. In CEM cells exposed for 15-240 minutes at 10 μM, it induces both primary and secondary DNA damage, specifically interstrand DNA cross-links (ISC) and DNA-protein cross-links (DPC). Additionally, (rel)-Oxaliplatin shows significant cytotoxicity against a diverse panel of cancer cell lines, including bladder carcinoma (RT4, TCCSUP), ovarian carcinoma (A2780), colon carcinoma (HT-29), glioblastoma (U-373MG, U-87MG), and melanoma (SK-MEL-2, HT-144), with IC50 values ranging from 0.17 to 30.9 μM after 24 hours of exposure. Detailed analyses on cell viability, protein expression, and cell cycle progression reveal its mechanisms of action, such as dose- and time-dependent reductions in cell viability, modulation of apoptotic protein expression (decreasing Bcl-2 and Bcl-xL, increasing Bax), and an increase in the percentage of apoptotic cells, thus demonstrating its broad and effective anti-tumor activities. |
| In vivo | (rel)-Oxaliplatin, administered intraperitoneally at dosages of 5-10 mg/kg over a period of 32 days, effectively inhibits tumor growth in nude mice. This was observed in a study using HCCLM3 tumor xenografts, where the treatment resulted in a significant reduction in tumor volume. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Company Profile Introduction
TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 40+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and small molecule compounds.
170+ Compound Libraries， 10000+ Noval Small Molecucles，16000+ Nature Compounds
TargetMol diligently updates and offers over 170 types of compound libraries and a wide range of high-quality research chemicals, including inhibitors, activators, natural products, peptides, antibodies , and novel life-science kits for laboratory and scientific use. In addition, our lab allows us to conduct CADD (computer-aided drug design) and chemical synthesis to meet the customization needs of our clients.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $5.00/1KG |
VIP1Y
|
Wuhan JiyunZen Tech Co., Ltd.
|
2025-05-30 | |
| $0.00/1g |
VIP1Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2024-08-09 | |
| $0.00/1KG |
VIP2Y
|
Hangzhou Hyper Chemicals Limited
|
2024-06-28 | |
| $1.10/1g |
VIP5Y
|
Dideu Industries Group Limited
|
2021-07-02 | |
| $0.00/1Kg |
VIP6Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2020-04-30 | |
| $1.00/1kg |
VIP7Y
|
Career Henan Chemical Co
|
2018-12-22 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, Massachusetts, USA
INQUIRY